Phone Number
(800) 210-7017
(800) 210-7017
Adding PRP isn’t a new business; it’s a high-margin cash-pay layer dropped onto a schedule you already run. The economics behave more like an elective procedure line than a billed service, which is why the question you really need to answer isn’t “what does PRP earn” but “how cleanly does it slot into your existing flow.” Get that right and you’re looking at a service with seventy-plus percent gross margins and a payback measured in months, not years.
A mature PRP line running ten to twenty cases per week can contribute several hundred thousand dollars of mostly incremental annual revenue at gross margins commonly above seventy percent.
The price card for PRP is tighter than most physicians expect, and the bands are remarkably consistent across geographies for similar protocols. Where you land inside the band is driven less by clinical sophistication than by your local competitive density and how confidently you can explain the protocol to a cash-paying patient. What you collect, however, is clean: cash at the point of service, no payer adjustment, no contractual writedown.
| Site / Protocol | Typical Cash Price |
|---|---|
| Single knee, single-spin | $800 to $1,000 |
| Shoulder or hip | $600 to $1,200 |
| Tendon (epicondyle, plantar, Achilles) | $500 to $900 |
| Specialty protocol (leukocyte-poor, double-spin) | $1,200 to $2,000 |
| Three-injection knee series | $2,100 to $2,700 |
A single-joint PRP injection prices in a band of six hundred to twelve hundred dollars in U.S. orthopedic and pain management practices, with eight hundred to one thousand dollars representing the most common quoted price for a single knee.
The capital wall to enter PRP is low, which is exactly why the service has spread so quickly across orthopedic and pain management groups. The line most practices underfund isn’t the centrifuge; it’s the launch marketing, and that’s where a clean pro forma quietly falls apart. Plan the hardware and plan the patient flow with equal weight or the equipment sits.
A practice can realistically stand up a credible PRP service line for fifteen to forty thousand dollars in first-year capital and launch spending, with most of the hardware qualifying as Section 179 property expensable in year one.
On paper PRP is a high-margin procedure, but the margin compresses fast if the cost stack isn’t tracked honestly. Most practices price confidently but allocate sloppily, then wonder why the income statement reads softer than the price card promised. The fix is granular: count every dollar that touches the case, not just the kit on the shelf.
A one thousand dollar single-joint procedure typically lands at one hundred fifty to two hundred fifty dollars of true variable plus directly allocable cost, producing a gross margin in the seventy-five to eighty-five percent range.
Break-even arrives faster than most physicians intuit because the contribution margin per case is doing the heavy lifting. The real risk to the timeline isn’t pricing or cost, both of which are predictable; it’s whether your consultations actually convert. A practice that books twenty consults a week and closes two is a low-volume practice no matter what the price card says.
A mid-market practice with thirty thousand dollars of setup spending and a one thousand dollar price point reaches break-even at approximately thirty-eight procedures, achievable in roughly two months at five paid cases per week.
Volume modeling has to start with the panel you already have, not with the market you wish you had. Roughly fifteen to twenty-five percent of your active musculoskeletal patients are clinically reasonable PRP candidates, but only a slice of that group will convert in any given quarter because cost, prior conservative care, and timing relative to a surgical recommendation all gate the call. The ramp is predictable if you let internal conversion lead and net-new acquisition follow.
A typical practice ramps from two to four procedures per week in months one through three to a steady state of ten to fifteen procedures per week per active provider by months nine through twelve, with consultation-to-procedure conversion typically running thirty-five to fifty-five percent.
Head to head against the covered injections you already do, PRP wins on most financial metrics and loses on a couple that matter. The big win is revenue per chair hour and the elimination of the ninety-day insurance receivable cycle. The trade is that you’re carrying the full patient-affordability risk yourself, with no payer to backstop a price the patient can’t meet, and an unconverted consult is fully sunk clinical time.
| Metric | Corticosteroid (covered) | PRP (cash-pay) |
|---|---|---|
| Net per injection | $70 to $150 | $800 to $1,000 |
| Revenue per chair hour | $200 to $600 | ~$3,000 at 3 cases per hour |
| Receivable cycle | 90+ days | Collected up front |
| Prior auth and denial work | Required | None |
| Patient-affordability risk | Carried by payer | Carried by practice |
A PRP injection priced at one thousand dollars with near-complete revenue realization yields six to ten times the net revenue of a corticosteroid injection in the same chair time.
Looking only at the injection fee understates what PRP actually does to the income statement. Most of the visible activity around the procedure either generates its own billable revenue or feeds adjacent service lines you already monetize. The right frame is that PRP is the front door, not the whole house.
When honestly measured, the full revenue impact of a PRP service line including downstream consults, bracing, physical therapy, and conversion to higher-priced regenerative procedures is two to four times the direct injection revenue.
A pro forma without a downside column is wishful thinking. Practices that model fifty percent conversion and land at twenty-five percent aren’t unprofitable, but they’re doing half the projected volume on the same fixed cost base, which turns a strong-margin line into a marginal one and pushes break-even from three months to nine. The risks worth modeling aren’t exotic; they’re predictable enough to put numbers on.
The single most common cause of disappointing PRP ROI is conversion underperformance, where a practice modeling fifty percent consultation-to-procedure conversion actually lands at twenty-five percent and runs roughly half the projected volume on the same fixed-cost base.
